Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive perampanel for primary generalized tonic-clonic seizures
NL-OMON38310Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2011
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perampanel in idiopathic epilepsy (IGE) and generalized tonic-clonic seizure (GTCS) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Sep 2011; status: active, not recruiting.
02
Drugs
perampanel
03
Conditions
idiopathic epilepsy (IGE)generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NL-OMON38310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38310.